The 1602 study was a clinical trial done to test the safety and efficacy of Myozyme in the...

Continued progress is being made in the Pompe program at Genzyme, with the goal of obtaining worldwide regulatory...

For Immediate Release December 20, 2004 Media Contact: Bo Piela 671-768-6579 Investor Contact: Sally Curley 617-768-6140 CAMBRIDGE, MA—Genzyme...

Genzyme is still on track for the Marketing Authorisation Application (MAA) filing in December with the European regulatory...

Infantile-Onset Expanded Access Program Enrollment in the Infantile Expanded Access Program is currently on-going. Physicians who may have...

Genzyme’s Pompe Program has progressed on many fronts over the last 6 months, and we are optimistic that...

IPA Board – We wanted to provide some more information with regards to the recent change to the...

1. Late-onset Observational Study (LOPOS) Genzyme is currently enrolling a prospective observational study in approximately 60 patients with...

A press release from Genzyme on late onset Enzyme Replacement Therapy (ERT) and Expanded Access Programs (EAPs).

Genzyme collaborates with patient organizations globally to communicate with people affected by Pompe disease. As part of these...